Monte Rosa Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Depreciation & Amortization Growth & History (GLUE)
Monte Rosa Therapeutics's depreciation and amortization was $10.9M for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.9M | $635,000 | +6.21% |
| 2024 | 2024-12-31 | $10.2M | $1.9M | +22.82% |
| 2023 | 2023-12-31 | $8.3M | $2.1M | +33.26% |
| 2022 | 2022-12-31 | $6.2M | $4.1M | +192.92% |
| 2021 | 2021-12-31 | $2.1M | $1.6M | +297.02% |
| 2020 | 2020-12-31 | $537,000 | — | — |
Monte Rosa Therapeutics quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.6M | −$121,000 | −4.42% |
| Q1 2026 | 2026-03-31 | $2.7M | $50,000 | +1.91% |
| Q4 2025 | 2025-12-31 | $2.1M | — | — |
| Q3 2025 | 2025-09-30 | $2.7M | $51,000 | +1.90% |
| Q2 2025 | 2025-06-30 | $2.7M | $469,000 | +20.65% |
| Q1 2025 | 2025-03-31 | $2.6M | −$75,000 | −2.78% |
| Q3 2024 | 2024-09-30 | $2.7M | $347,000 | +14.87% |
| Q2 2024 | 2024-06-30 | $2.3M | $180,000 | +8.61% |
| Q1 2024 | 2024-03-31 | $2.7M | $746,000 | +38.24% |
| Q3 2023 | 2023-09-30 | $2.3M | $301,000 | +14.81% |
| Q2 2023 | 2023-06-30 | $2.1M | $202,000 | +10.69% |
| Q1 2023 | 2023-03-31 | $2.0M | $798,000 | +69.21% |
| Q3 2022 | 2022-09-30 | $2.0M | $1.4M | +238.83% |
| Q2 2022 | 2022-06-30 | $1.9M | $1.5M | +372.25% |
| Q1 2022 | 2022-03-31 | $1.2M | $879,000 | +320.80% |
| Q3 2021 | 2021-09-30 | $600,000 | $429,000 | +250.88% |
| Q2 2021 | 2021-06-30 | $400,000 | — | — |
| Q1 2021 | 2021-03-31 | $274,000 | — | — |
| Q3 2020 | 2020-09-30 | $171,000 | — | — |
Monte Rosa Therapeutics depreciation and amortization trends
Over the last five fiscal years, Monte Rosa Therapeutics's depreciation and amortization increased from $537,000 to $10.9M, a change of $10.3M. The latest reported quarter, Q2 2026, shows $2.6M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗